SG11201906933SA - Functionalized erythroid cells - Google Patents

Functionalized erythroid cells

Info

Publication number
SG11201906933SA
SG11201906933SA SG11201906933SA SG11201906933SA SG11201906933SA SG 11201906933S A SG11201906933S A SG 11201906933SA SG 11201906933S A SG11201906933S A SG 11201906933SA SG 11201906933S A SG11201906933S A SG 11201906933SA SG 11201906933S A SG11201906933S A SG 11201906933SA
Authority
SG
Singapore
Prior art keywords
suite
cambridge
vassar
international
rule
Prior art date
Application number
SG11201906933SA
Inventor
Tom Wickham
Tiffany Chen
Xuqing Zhang
Carolyn Hudak
Jordi Mata-Fink
Sivan Elloul
Billy Law
Lenka Hoffman
Kristian Teichert
Shamael Dastagir
Original Assignee
Rubius Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubius Therapeutics Inc filed Critical Rubius Therapeutics Inc
Publication of SG11201906933SA publication Critical patent/SG11201906933SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0641Erythrocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/18Erythrocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/001Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)

Abstract

Substratereactive moiety \ Click handle 1 Click handle 2 /agen t\ Coupling reagent 1 Coupling reagent 2 Click handle 2 Click handle 1 Substrate-reactive moiety 1 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 August 2018 (23.08.2018) WI P0 I PC T limion omits onolomolu onolomiomom (10) International Publication Number WO 2018/151829 Al (51) International Patent Classification: C12N 5/078 (2010.01) (21) International Application Number: PCT/US2018/000042 (22) International Filing Date: 16 February 2018 (16.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/460,589 17 February 2017 (17.02.2017) US 62/542,142 07 August 2017 (07.08.2017) US (71) Applicant: RUBIUS THERAPEUTICS, INC. [US/US]; 325 Vassar St Suite 1A, Cambridge, MA 02139 (US). (72) Inventors: WICKHAM, Tom; 325 Vassar St Suite 1A, Cambridge, MA 02139 (US). CHEN, Tiffany, F.; 325 Vas- sar St Suite 1A, Cambridge, MA 02139 (US). ZHANG, Xuqing; 325 Vassar St Suite 1A, Cambridge, MA 02139 (US). HUDAK, Carolyn; 325 Vassar St Suite 1A, Cam- bridge, MA 02139 (US). MATA-FINK, Jordi; 325 Vas- sar St Suite 1A, Cambridge, MA 02139 (US). ELLOUL, Sivan; 325 Vassar St Suite 1A, Cambridge, MA 02139 (US). LAW, Billy; 325 Vassar St Suite 1A, Cambridge, MA 02139 (US). HOFFMAN, Lenka; 325 Vassar St Suite 1A, Cambridge, MA 02139 (US). TEICHERT, Kristian, Eric; 325 Vassar St Suite 1A, Cambridge, MA 02139 (US). DAS- TAGIR, Shamael, Rabia; 325 Vassar St Suite 1A, Cam- bridge, MA 02139 (US). (74) Agent: YANG, Peter et al.; Lando & Anastasi, LLP, River- front Office Park, One Main Street, Suite 1100, Cambridge, MA 02142 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, — (54) Title: FUNCTIONALIZED ERYTHROID CELLS 1111 A Click srt s ure FIG. 1 0 (57) : Described herein are novel preparations of functionalized erythroid cells and related compositions, reagents, and methods \" for use in human pharmaceutical and veterinary applications. C [Continued on next page] WO 2018/151829 Al MIDEDIMOMOIDEIREEM311011111010MODEVOIS UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))
SG11201906933SA 2017-02-17 2018-02-16 Functionalized erythroid cells SG11201906933SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762460589P 2017-02-17 2017-02-17
US201762542142P 2017-08-07 2017-08-07
PCT/US2018/000042 WO2018151829A1 (en) 2017-02-17 2018-02-16 Functionalized erythroid cells

Publications (1)

Publication Number Publication Date
SG11201906933SA true SG11201906933SA (en) 2019-09-27

Family

ID=61873874

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906933SA SG11201906933SA (en) 2017-02-17 2018-02-16 Functionalized erythroid cells

Country Status (12)

Country Link
US (2) US11020435B2 (en)
EP (1) EP3583202A1 (en)
JP (1) JP2020507329A (en)
KR (1) KR20190117667A (en)
CN (1) CN110520522A (en)
AU (1) AU2018221227A1 (en)
BR (1) BR112019016951A2 (en)
CA (1) CA3052142A1 (en)
IL (1) IL268359A (en)
MX (1) MX2019009839A (en)
SG (1) SG11201906933SA (en)
WO (1) WO2018151829A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016011195A2 (en) 2013-11-18 2017-09-19 Rubius Therapeutics Inc ENUCLEATED ERYTHROID CELLS AND THEIR METHODS OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND THEIR USE, USE OF AN ERYTHROID CELL POPULATION, BIORACTOR, CELL MIXTURE AND MEDICAL DEVICE
HUE054471T2 (en) 2014-04-01 2021-09-28 Rubius Therapeutics Inc Methods and compositions for immunomodulation
CN108778298A (en) 2016-01-11 2018-11-09 鲁比厄斯治疗法股份有限公司 Composition related with the multi-mode therapeutic cells system of immunological adaptation disease and method
US11020435B2 (en) * 2017-02-17 2021-06-01 Rubius Therapeutics, Inc. Functionalized erythroid cells
WO2019090148A2 (en) 2017-11-03 2019-05-09 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems for tumor growth inhibition
KR20200104887A (en) * 2017-12-23 2020-09-04 루비우스 테라퓨틱스, 아이엔씨. Artificial antigen presenting cells and methods of use
US20190330591A1 (en) 2018-01-10 2019-10-31 Rubius Therapeutics, Inc. Amplifiable rnas for therapeutic cell systems
SG11202008261WA (en) 2018-03-08 2020-09-29 Rubius Therapeutics Inc Therapeutic cell systems and methods for treating cancer and infectious diseases
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
CA3125567A1 (en) 2019-01-18 2020-07-23 Flagship Pioneering, Inc. Trem compositions and uses thereof
BR112021016451A2 (en) 2019-02-20 2021-11-09 Rubius Therapeutics Inc Engineered erythroid cell including chargeable antigen-presenting polypeptides and methods of use
CA3128626A1 (en) 2019-03-04 2020-09-10 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides and pharmaceutical compositions thereof
KR20210142678A (en) 2019-03-25 2021-11-25 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 Compositions comprising modified circular polyribonucleotides and uses thereof
CN114269921A (en) 2019-05-31 2022-04-01 旗舰创业股份有限公司 Use of TREM compositions to modulate tRNA cells
JP2022537154A (en) 2019-06-14 2022-08-24 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー circular RNA for cell therapy
WO2020257730A1 (en) 2019-06-19 2020-12-24 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
US20220364075A1 (en) 2019-11-04 2022-11-17 Flagship Pioneering, Inc. Methods of modifying a nucleic acid sequence
US20220364092A1 (en) 2019-11-04 2022-11-17 Flagship Pioneering, Inc. Trem compositions for con-rare codons and related uses
US20230340451A1 (en) 2020-01-29 2023-10-26 Flagship Pioneering Innovations Vi, Llc Compositions comprising linear polyribonucleotides for protein modulation and uses thereof
TW202142689A (en) 2020-01-29 2021-11-16 美商旗艦先鋒創新有限責任公司 Compositions for translation and methods of use thereof
TW202142239A (en) 2020-01-29 2021-11-16 美商旗艦先鋒創新有限責任公司 Delivery of compositions comprising circular polyribonucleotides
WO2021162731A1 (en) 2020-02-10 2021-08-19 Rubius Therapeutics, Inc. Engineered erythroid cells including hla-g polypeptides and methods of use thereof
CN115335064A (en) * 2020-03-20 2022-11-11 西湖生物医药科技(杭州)有限公司 Modified red blood cells and their use for delivery of agents
WO2021236980A1 (en) 2020-05-20 2021-11-25 Flagship Pioneering Innovations Vi, Llc Coronavirus antigen compositions and their uses
WO2021236952A1 (en) 2020-05-20 2021-11-25 Flagship Pioneering, Inc. Compositions and methods for producing human polyclonal antibodies
CN116194139A (en) 2020-05-20 2023-05-30 旗舰创业创新第六有限责任公司 Immunogenic compositions and uses thereof
WO2021243301A2 (en) 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc. Trem compositions and methods relating thereto
CN116018405A (en) 2020-05-29 2023-04-25 旗舰先锋创新Vi有限责任公司 TREM compositions and related methods
EP4167984A1 (en) 2020-06-23 2023-04-26 Flagship Pioneering, Inc. Anti-viral compounds and methods of using same
EP4208196A1 (en) 2020-09-03 2023-07-12 Flagship Pioneering Innovations VI, LLC Immunogenic compositions and uses thereof
CA3206285A1 (en) 2020-12-23 2022-06-30 Flagship Pioneering, Inc. Compositions of modified trems and uses thereof
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CN117730143A (en) * 2021-07-13 2024-03-19 西湖生物医药科技(杭州)有限公司 Cells modified by conjugated N-terminal glycine and uses thereof
WO2023009547A1 (en) 2021-07-26 2023-02-02 Flagship Pioneering Innovations Vi, Llc Trem compositions and uses thereof
AU2022346861A1 (en) 2021-09-17 2024-03-28 Flagship Pioneering Innovations Vi, Llc Compositions and methods for producing circular polyribonucleotides
TW202322826A (en) 2021-10-18 2023-06-16 美商旗艦先鋒創新有限責任公司 Compositions and methods for purifying polyribonucleotides
WO2023097003A2 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and their uses
WO2023096963A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
WO2023096990A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovation Vi, Llc Coronavirus immunogen compositions and their uses
TW202340461A (en) 2021-12-22 2023-10-16 美商旗艦先鋒創新有限責任公司 Compositions and methods for purifying polyribonucleotides
TW202342064A (en) 2021-12-23 2023-11-01 美商旗艦先鋒創新有限責任公司 Circular polyribonucleotides encoding antifusogenic polypeptides
WO2023196593A1 (en) * 2022-04-08 2023-10-12 The University Of North Carolina At Chapel Hill Antigen-independent targeted delivery of therapeutic agents
WO2023220083A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
WO2023220729A2 (en) 2022-05-13 2023-11-16 Flagship Pioneering Innovations Vii, Llc Double stranded dna compositions and related methods
WO2023230549A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulation of tumor suppressors and oncogenes
WO2023230566A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating cytokines
WO2023230573A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulation of immune responses
WO2023230578A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating circulating factors
WO2023230570A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating genetic drivers
WO2023250112A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024097664A1 (en) 2022-10-31 2024-05-10 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
WO2024102799A1 (en) 2022-11-08 2024-05-16 Flagship Pioneering Innovations Vi, Llc Compositions and methods for producing circular polyribonucleotides

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070243137A1 (en) 2006-04-18 2007-10-18 Nanoprobes, Inc. Cell and sub-cell methods for imaging and therapy
US8501478B2 (en) 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
KR20090094812A (en) 2006-10-18 2009-09-08 더 스크립스 리서치 인스티튜트 Genetic incorporation of unnatural amino acids into proteins in mammalian cells
EP2057998A1 (en) 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Use of modified cells for the treatment of multiple sclerosis
US20110086424A1 (en) * 2008-05-06 2011-04-14 Advanced Cell Technology, Inc. Methods for producing enucleated erythroid cells derived from pluripotent stem cells
US20100040546A1 (en) 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US20120034156A1 (en) 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
CA2753189A1 (en) 2009-02-21 2010-08-26 Nadya Belcheva Medical devices having activated surfaces
WO2011059586A2 (en) 2009-10-30 2011-05-19 The Regents Of The University Of Michigan Multifunctional small molecules
CA2758390A1 (en) * 2011-11-14 2013-05-14 Ibc Pharmaceuticals, Inc. Stem cell targeting with dock-and-lock (dnl) complexes
AU2013203832B2 (en) 2012-03-13 2016-09-15 Celularity Inc. Modified erythrocyte precursor cells and uses thereof
FR2997082B1 (en) 2012-10-18 2015-02-13 Centre Nat Rech Scient MULTIFUNCTIONAL COUPLING REAGENTS WITH AZLACTONE FUNCTION.
US10260038B2 (en) 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
ES2901383T3 (en) 2013-05-10 2022-03-22 Whitehead Inst Biomedical Res In vitro production of red blood cells with sortase-markable proteins
JP2015032986A (en) 2013-08-02 2015-02-16 住友電気工業株式会社 Radio terminal device, radio base station device, communication system, radio access providing method, and communication control program
BR112016011195A2 (en) 2013-11-18 2017-09-19 Rubius Therapeutics Inc ENUCLEATED ERYTHROID CELLS AND THEIR METHODS OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND THEIR USE, USE OF AN ERYTHROID CELL POPULATION, BIORACTOR, CELL MIXTURE AND MEDICAL DEVICE
HUE054471T2 (en) 2014-04-01 2021-09-28 Rubius Therapeutics Inc Methods and compositions for immunomodulation
US10053683B2 (en) 2014-10-03 2018-08-21 Whitehead Institute For Biomedical Research Intercellular labeling of ligand-receptor interactions
US20180110831A1 (en) 2015-03-09 2018-04-26 Stc.Unm Cd 47 containing porous nanoparticle supported lipid bilayers (protocells) field of the invention
WO2016183482A1 (en) 2015-05-13 2016-11-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
CN108778298A (en) * 2016-01-11 2018-11-09 鲁比厄斯治疗法股份有限公司 Composition related with the multi-mode therapeutic cells system of immunological adaptation disease and method
WO2017152077A1 (en) 2016-03-04 2017-09-08 Whitehead Institute For Biomedical Research Efficient generation of human red blood cells via enriching peripheral blood erythroid progenitors
BR112019000195A2 (en) 2016-07-07 2019-04-24 Rubius Therapeutics, Inc. compositions and methods related to therapeutic cellular systems expressing exogenous rna
CN110225756A (en) * 2016-12-02 2019-09-10 鲁比厄斯治疗法股份有限公司 Composition relevant to the cell system for penetrating solid tumor and method
US11020435B2 (en) * 2017-02-17 2021-06-01 Rubius Therapeutics, Inc. Functionalized erythroid cells
EP3672602A1 (en) * 2017-08-22 2020-07-01 Rubius Therapeutics, Inc. Lipid nanoparticle methods and compositions for producing engineered erythroid cells
WO2019090148A2 (en) 2017-11-03 2019-05-09 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems for tumor growth inhibition
US20190201548A1 (en) 2017-12-29 2019-07-04 Rubius Therapeutics, Inc. Gene editing and targeted transcriptional modulation for engineering erythroid cells
US20190330591A1 (en) 2018-01-10 2019-10-31 Rubius Therapeutics, Inc. Amplifiable rnas for therapeutic cell systems
AU2019394875A1 (en) * 2018-12-03 2021-06-17 Rubius Therapeutics, Inc. Artificial antigen presenting cells including HLA-E and HLA-G molecules and methods of use
BR112021016451A2 (en) * 2019-02-20 2021-11-09 Rubius Therapeutics Inc Engineered erythroid cell including chargeable antigen-presenting polypeptides and methods of use
CN114007627A (en) * 2019-04-26 2022-02-01 鲁比厄斯治疗法股份有限公司 Buffered compositions comprising enucleated erythroid cells
WO2020243006A1 (en) * 2019-05-24 2020-12-03 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells
WO2021162731A1 (en) * 2020-02-10 2021-08-19 Rubius Therapeutics, Inc. Engineered erythroid cells including hla-g polypeptides and methods of use thereof

Also Published As

Publication number Publication date
RU2019129088A (en) 2021-03-17
WO2018151829A1 (en) 2018-08-23
RU2019129088A3 (en) 2021-03-25
AU2018221227A1 (en) 2019-08-15
CN110520522A (en) 2019-11-29
JP2020507329A (en) 2020-03-12
EP3583202A1 (en) 2019-12-25
US11020435B2 (en) 2021-06-01
BR112019016951A2 (en) 2020-05-26
US20210290682A1 (en) 2021-09-23
US20180344770A1 (en) 2018-12-06
KR20190117667A (en) 2019-10-16
MX2019009839A (en) 2019-10-22
IL268359A (en) 2019-09-26
CA3052142A1 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
SG11201906933SA (en) Functionalized erythroid cells
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201909322VA (en) Treatment of asthma with anti-tslp antibody
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201907653QA (en) Compositions and methods for enhanced gene expression
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201811405QA (en) Improved differentiation method
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201805137XA (en) Virus encoding an anti-tcr-complex antibody or fragment
SG11202000312UA (en) Encapsulated polynucleotides and methods of use
SG11201909728XA (en) Constructs specifically recognizing glypican 3 and uses thereof
SG11201810466PA (en) Compositions and methods related to engineered fc constructs
SG11201903287PA (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201809872TA (en) Using hardware based secure isolated region to prevent piracy and cheating on electronic devices
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201907434RA (en) Compositions and methods for immunooncology
SG11201810872UA (en) Composition and method for reducing neutropenia
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201901228QA (en) Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
SG11201805001UA (en) Method of treating influenza a
SG11201907420VA (en) Inhibition of smarca2 for treatment of cancer
SG11201900609PA (en) Method and system for providing buffer solutions